Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer

Lectura recomendada por el Lectura recomendada por el Dr. Mauricio Luongo. 

Conferencia 2024: “Presente de los tratamientos con Inmunoradioterapia.”

• Autores: Chiaojung Jillian Tsai, Jonathan T Yang, Narek Shaverdian et al.
• Fuente: Lancet 2019; 393: 2051–58.

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

Descargar